JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 25 July 2005. doi:10.1083/jcb1703rr2
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 170, Number 3, 336-336
This Article
Right arrow Full Text (PDF, 311K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Roundup

MMPs rearrange DNA


Matrix metalloproteases (MMPs) create havoc both outside and inside a cell to pave the way for tumorigenesis, based on findings from Derek Radisky, Mina Bissell (Berkeley Lab, Berkeley, CA), and colleagues.

MMPs are known to support cancer progression by their ability to degrade the matrix and clear the way for invasion and metastasis. Bissell's lab now shows that MMP-3 can also stimulate genomic instability, a key tumor characteristic, in mammary epithelial cells.

The genomic instability stems from mitochondrial production of the reactive oxygen species (ROS) superoxide, which altered the genotype and phenotype of mammary epithelial cells. The authors show that ROS are sufficient to reproduce the effects of MMP treatment, and that quenching ROS prevents MMP-3–induced genomic rearrangements and cell motility. The authors are now investigating the link between ROS and motility.

Superoxide is made in response to the induction of an overactive splice variant of the Rac1 GTPase in MMP-treated cells. Expression of this variant, called Rac1b, induced ROS in the absence of MMPs. The MMP-induced cell motility that accompanies invasiveness was prevented by silencing Rac1b, which might be a new target for antitumor therapies. It is unclear how MMPs cause the alternative splicing of Rac1. Perhaps ß-catenin, which moves to the nucleus upon E-cadherin cleavage by MMPs, affects splicing as well as transcription. {rr_end}

Reference:

Radisky, D.C., et al. 2005. Nature. 436:123–127.[CrossRef][Medline]



Nicole LeBrasseur

lebrasn{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 311K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents